Shree Ganesh Remedies Q2 FY27: Consolidated PAT Falls 67% YoY as Margins Nearly Halve

Shree Ganesh Remedies' consolidated Q2 FY27 (quarter ended September 30, 2026) revenue from operations came in at ₹23.29 Cr, down 23.2% YoY from ₹30.32 Cr, while consolidated PAT fell 67.1% YoY to ₹1.63 Cr from ₹4.96 Cr — the YoY decline remains broad-based even though both lines rebounded sharply sequentially (revenue +62.2% QoQ, PAT +45.5% QoQ) off a weak Q1 FY27 base that was itself down 42% YoY. Standalone and consolidated results are closely aligned (PAT ₹1.6346 Cr standalone vs ₹1.6299 Cr consolidated), so there is no basis divergence to flag. The YoY decline is concentrated in margins rather than volumes alone: operating margin (OPM) compressed to roughly 16.9% from 31.7% a year ago and 23.3% last quarter, and net margin (NPM) fell to 7.0% from 16.0% YoY. With cost of materials and other expenses rising faster than revenue even as revenue recovered sequentially, the squeeze sits on the gross/operating line rather than tax or finance costs, whose share of revenue stayed comparatively stable. No exceptional items, minority-interest swings, or other one-offs are disclosed in this filing, so the entire YoY move in PAT reflects this margin compression plus the smaller revenue base. No broker previews or consensus estimates for this specific quarter turned up in search, so vsStreet is unknown — this is a small-cap with limited visible analyst coverage. Against management's own framing from the Q4 FY26 concall — a 'gradual improvement in momentum through FY27' driven by new Block-7 capacity commencing production in Q2 FY27 and CRAMS traction building later in the year, with a long-term EBITDA margin target of 26-28% — the quarter is mixed: the 62.2% QoQ revenue jump is directionally consistent with Block-7 ramping as guided, but the YoY comparison (the primary read) is still a steep decline, and OPM at ~16.9% sits well below both last year's print and the stated long-term target, so on the margin dimension guidance is being missed so far. This filing carries no attached press release or MD&A commentary, so management's own characterization of the quarter cannot be cross-checked here. The quarter's other corporate developments — a new Company Secretary appointed October 3, 2026, trading-window closure from September 26 ahead of results, and the 31st AGM held September 12, 2026 — are administrative and don't bear on the numbers. H1 FY27 cumulative consolidated revenue of ₹37.65 Cr (down ~31.5% YoY) and PAT of ₹2.75 Cr (down ~67.3% YoY) confirm the weakness spans both quarters of the half, not just this one.